While the landscape of healthcare in the United States continues to change, at MyMD we continue to move science forward by arming researchers with creative solutions that challenge previous scientific understandings of immuno-metabolic systems in the body.
This year we have presented our Investigational New Drug (IND) application for our lead candidate, MyMD-1, to the US Food and Drug Administration and are proceeding with a Phase 1 trial in healthy human volunteers for the treatment of Hashimoto’s Thyroiditis.
It is established that a balanced immunometobolic system is essential to maintaining healthy homeostasis; however, under stress or as we age, this complex system can commonly enter a state of deregulation causing disease and aging. MYMD-1 is a novel drug platform that is being developed to treat a broad range of conditions, including autoimmune disease, cardiovascular disease, neurological disease and aging by addressing deregulation of the immunometabolic system.
MyMD Pharmaceuticals, Inc. is a clincial-stage drug development company pursuing the discovery of mechanisms of diseases that affect an aging population, followed by implementation of treatments to prevent or cure them.